ProCE Banner Activity

Novel Therapies, Improving Adherence, and Reducing Disparities in Psoriasis Care

Clinical Thought

This expert commentary reviews strategies for incorporating new and emerging therapies, improving medication adherence, and addressing healthcare disparities, for patients with moderate to severe psoriasis.

Released: September 16, 2022

Expiration: September 15, 2023

No longer available for credit.

Share

Faculty

Steven Feldman

Steven Feldman, MD, PhD

Professor
Department of Dermatology
Wake Forest University School of Medicine
Winston-Salem, North Carolina

Provided by

Provided by Partners for Advancing Clinical Education (PACE)

ProCE Banner
ProCE Banner

Supporters

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Novartis Pharmaceuticals Corporation

Faculty Disclosure

Primary Author

Steven Feldman, MD, PhD

Professor
Department of Dermatology
Wake Forest University School of Medicine
Winston-Salem, North Carolina

Steven Feldman, MD, PhD: consultant/speaker: AbbVie, Accordant, Almirall, Alvotech, Amgen, Arcutis, Arena, Argenx, Biocon, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Forte, Helsinn, Janssen, Leo, Lilly, Mylan, Novartis, Pfizer, Samsung, Sanofi, Sun Pharma, Union Chimique Belge (UCB), vTv Therapeutics, Voluntis; researcher: Galderma, Janssen, Lilly, Pfizer, Regeneron; stock/stock options: Sensal Health.